A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022

AGOURA HILLS, Calif.--(BUSINESS WIRE)-- #A2Bio--A2 Biotherapeutics, Inc., “A2 Bio”, is a biotechnology company focused on the development of first-in-class T cell therapeutics to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to selectively kill tumor cells while protecting normal cells. A2 Bio today announced four poster...

Click to view original post